Spruce Biosciences Inc
OTC:SPRB

Watchlist Manager
Spruce Biosciences Inc Logo
Spruce Biosciences Inc
OTC:SPRB
Watchlist
Price: 85.24 USD 1.48% Market Closed
Market Cap: $91.2m

Net Margin

-6 869.3%
Current
Declining
by 5 071.6%
vs 3-y average of -1 797.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-6 869.3%
=
Net Income
$-47.9m
/
Revenue
$697k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-6 869.3%
=
Net Income
$-47.9m
/
Revenue
$697k

Peer Comparison

Country Company Market Cap Net
Margin
US
Spruce Biosciences Inc
NASDAQ:SPRB
91.2m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4th
Based on 15 072 companies
4th percentile
-6 869.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Spruce Biosciences Inc
Glance View

Market Cap
91.2m USD
Industry
Biotechnology

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Daly City, California and currently employs 15 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing and commercializing therapies for rare endocrine disorders. The firm's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. The company has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.

SPRB Intrinsic Value
136.71 USD
Undervaluation 38%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-6 869.3%
=
Net Income
$-47.9m
/
Revenue
$697k
What is Spruce Biosciences Inc's current Net Margin?

The current Net Margin for Spruce Biosciences Inc is -6 869.3%, which is below its 3-year median of -1 797.7%.

How has Net Margin changed over time?

Over the last 2 years, Spruce Biosciences Inc’s Net Margin has decreased from -2 408.2% to -6 869.3%. During this period, it reached a low of -6 869.3% on Sep 30, 2025 and a high of -450.5% on Jun 30, 2024.

Back to Top